TAF + Emtricitabine + Rilpivirine Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: (TAF) – 25 mg + Emtricitabine – 200 mg + Rilpivirine – 25 mg

Reference Brands: Odefsey(US & EU)

Category: Anti Viral

Tenofovir alafenamide 25 mg, emtricitabine 200 mg and rilpivirine 25 mg fixed-dose tablets, a once-daily HIV-1 regimen, for national HIV programmes, importers, distributors and tender buyers.

Product Description:

This is a complete single-tablet antiretroviral regimen for HIV-1. It combines tenofovir alafenamide 25 mg and emtricitabine 200 mg, nucleoside or nucleotide reverse transcriptase inhibitors, with rilpivirine 25 mg, a non-nucleoside inhibitor, so reverse transcriptase is blocked at two sites. Tenofovir alafenamide delivers tenofovir into cells at a much lower dose than tenofovir disoproxil, giving lower blood tenofovir levels and less effect on kidney and bone markers. One tablet daily replaces three medicines.

It is used in adults and adolescents of at least 35 kg, to start treatment at a viral load of 100,000 copies per mL or less, or to switch suppressed patients. It must be taken with a meal for rilpivirine absorption. Proton pump inhibitors are contraindicated; H2 blockers go 12 hours before or 4 hours after, and antacids 2 hours before or 4 hours after. Rifampicin, carbamazepine, phenytoin and St John's wort are contraindicated. Hepatitis B is checked first, as stopping can trigger a flare.

Sourcing notes. This prescription-only antiretroviral is bought by national HIV programmes, hospitals and donor-funded tenders, where WHO prequalification or stringent regulatory approval is often required. Ask for the CTD or ACTD dossier with bioequivalence for all three components, zone IVb stability and a CoA per batch. Tenofovir alafenamide is moisture-sensitive, so reference packs are bottles with desiccant and child-resistant caps. Request the GMP certificate and CoPP, check local patent status, and state bottle count and required shelf life.